The prevention of neonatal group B streptococcal disease: A report by a working group of the Medical Screening Society

Journal of Medical Screening

Volumn 12, Issue 2, 2005, Pages 60-68

  Law, M R ^a   Palomaki, G ^b   Alfirevic, Z ^c   Gilbert, R ^d   Heath, P ^e   McCartney, C ^f   Reid, T ^g   Schrag, S ^h  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b WOMEN AND INFANTS HOSPITAL   (United States)

^c LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g NHS GRAMPIAN   (United Kingdom)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFAZOLIN; CLINDAMYCIN; PENICILLIN DERIVATIVE; POLYSACCHARIDE VACCINE; STREPTOCOCCUS VACCINE; TETANUS TOXOID;

ADOLESCENT; ADULT; BACTERIAL MENINGITIS; CLINICAL TRIAL; DELIVERY; DISABILITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HIGH RISK PREGNANCY; HUMAN; INFANT; NEWBORN; NEWBORN INFECTION; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONHUMAN; ONSET AGE; REVIEW; RISK FACTOR; SCREENING; SEPSIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; TERATOGENICITY; THROMBOSIS; UNITED KINGDOM;

ANTIBIOTIC PROPHYLAXIS; CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; FEMALE; GREAT BRITAIN; HUMANS; LABOR, OBSTETRIC; MALE; MASS SCREENING; PENICILLINS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK; RISK FACTORS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; TIME FACTORS; VACCINES;

EID: 20644472238     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1258/0969141053908366     Document Type: Review

References (55)

1. Farley MM, Harvey CR, Stull T, et al. A population-based assessment of invasive disease due to group B streptococcus in nonpregnant adults. N Engl J Med 1993;328:1807-11
2. Communicable Disease Surveillance Centre. Neonatal meningitis: a review of routine national data 1975-83. BMJ 1985;290:778-9
3. Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 2001;323:1-5
4. Gilbert GL. Vaccines for other neonatal infections. Expert Rev Vaccines 2004;3:371-4
5. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC. MMWR 2002;51:1-18 (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5111a1.htm)
6. Isaacs D, Royle JA, for the Australasian Study Group for Neonatal Infections. Intrapartum antibiotics and early onset neonatal sepsis cused by group B streptococcus and by other organisms in Australia. Pediatr Infect Dis J 1999;18:524-8
7. Jeffery HE, Lahra MM. Eight-year outcome of universal screening and intrapartum antibiotics for maternal group B streptococcal carriers. Pediatrics 1998;101:E2
8. Royal College of Obstetricians and Gynaecologists. Prevention of early onset neonatal group B streptococcal disease Guideline No. 36 2003, (http://www.rcog.org.uk/resources/Public/GroupB_strep_no36.pdf)
9. Kenyon S, Brocklehurst P, Blackburn A, Taylor DJ. Antenatal screening and intrapartum management of group B streptococcus in the UK. Br J Obstet Gynaecol 2004;111:226-30
10. Ramus RM, McIntire DD, Wendel Jr GD. Antibiotic chemoprophylaxis for group B strep is not necessary with elective cesarean section at term (abstract). Am J Obstet Gynecol 1999;180:S85
11. Heath PT, Balfour G, Weisner AM, et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 2004;363:292-4
12. Regan JA, Klebanoff MA, Nugent RP. The epidemiology of group B streptococcal colonization in pregnancy. Obstet Gynecol 1991;77:604-10
13. Davies HD, Miller MA, Faro S, Gregson D, Kehl SC, Jordan JA. Multicenter study of a rapid molecular-based assay for the diagnosis of group B streptococcus colonization in pregnant women. Clin Infect Dis 2004;39:1129-35
14. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States 1990: report from a multistate active surveillance system. MMWR 1992;41:25-32
15. Lukacs SL, Schoendorf KC, Schuchat S. Trends in sepsis-related neonatal mortality in the United States, 1985-1998. Pediatr Infect Dis J 2004;23:599-603
16. Moses LM, Heath PT, Wilkinson AR, Jeffery HE, Isaacs D. Early onset group B streptococcal neonatal infection in Oxford 1985-96. Arch Dis Child Fetal Neonatal Ed 1998;79:F148-9
17. Halliday E, Foote K, Dryden M, Down R, Ward J. Universal maternal screening for neonatal group B streptococcal disease. Lancet 2000;356:1407-8
18. Mifsud AJ, Efstratiou A, Charlett A, McCartney AC. Early onset neonatal group B streptococcal infection in London: 1990-9. Br J Obstet Gynaecol 2004;B111B:1006-11
19. Beardsall K, Thompson MH, Mulla RJ. Neonatal group B streptococcal infection in South Bedfordshire, 1993-199. Arch Dis Child Fetal Neonatal Ed 2000;82:F205-7
20. Oddie S, Embleton ND, on behalf of the Northern Neonatal Network. Risk factors for early onset group B streptococcal sepsis: case-control study. BMJ 2002;325:308-12
21. Hastings MJG, Easmon CSF, Neill J, Bloxham B, Rivers RPA. Group B streptococcal colonisation and the outcome of pregnancy. J Infect 1986;12:23-9
22. Luck S, Torny M, d'Agapeyeff K, et al. Estimated early-onset group B streptococcal neonatal disease. Lancet 2003;361:1953-4
23. Easmon CSF. The carrier state: Group B streptococcus. J Antimicrob Chemother 1986;18:59-65
24. Gilbert R. Prenatal screening for group B streptococcal infection: gaps in the evidence. Int J Epidemiol 2003;33:2-8
25. Davies HD, Adair C, McGeer A, et al. Antibodies to capsular polysaccharides of group B streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate. J Infect Dis 2001;184:285-91
26. Weisner AM, Johnson AP, Lamagni TL, et al. Characterisation of Group B Streptococci from infants with invasive disease in England and Wales. Clin Infect Dis 2004;38:1203-8
27. de Cueto M, Sanchez M-J, Sampedro A, Miranda J-A, Herruzo A-J, Tosa-Fraile M. Timing of intrapartum ampicillin and prevention of vertical transmission of group B streptococcus. Obstet Gynecol 1998;91:112-4
28. Smaill F. Intrapartum antibiotics for Group B streptococcal colonisation. Cochrane Database Syst Rev 2002;3:CD00115
29. Allen UD, Navas L, Ling S. Effectiveness of intrapartum penicillin prophylaxis in preventing early onset group B streptococcal infection: results of a meta-analysis. Can Med Assoc J 1993;149:1659-65
30. Easmon CSF, Hastings MJG, Deeley J, Bloxham B, Rivers RPA, Marwood R. The effect of intrapartum chemoprophylaxis in the vertical transmission of group B streptococci. Br J Obstet Gynaecol 1983;90:633-5
31. Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986;314:1665-9
32. Morales WJ, Lim DV, Walsh AF. Prevention of neonatal group B streptococcal sepsis by the use of a rapid screening test and selective intrapartum chemoprophylaxis. Am J Obstet Gynecol 1986;155:979-83
33. Tuppurainen N, Hallman M. Prevention of neonatal group B streptococcal disease: intrapartum detection and chemoprophylaxis of heavily colonized parturients. Obstet Gynecol 1989;73:583-7
34. Mattoras R, Garcia-Perea A, Omenaca F, Diez-Enciso M, Madero R, Usandizaga JA. Intrapartum chemoprophylaxis of early-onset group B streptoococcal disease. Eur J Obstet Gynecol Reprod Biol 1991;40:57-62
35. McCartney AC. Prevention of early onset neonatal group B streptococcal infection. J Med Screen 2001;8:170-2
36. Gilbert RE, Pike K, Kenyon SL, Tarnow-Mordi W, Taylor DJ. The effect of prepartum antibiotics on the type of neonatal bacteraemia: insights from the MRC ORACLE trials. Br J Obstet Gynaecol 2004;111:1-3
37. Bergeron MG, Ke D, Ménard C, et al. Rapid detection of group B streptococci in pregnant women at delivery. N Engl J Med 2000;343:175-9
38. Schrag SL, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002;347:233-9
39. American Academy of Pediatrics. Guidelines for prevention of Group B streptococcal infection by chemoprophylaxis. Pediatrics 1992;90:775-8
40. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342:15-20
41. Factor SH, Whitney CG, Zywicki SS, et al. Effects of hospital policies based on 1996 group B streptococcal disease consensus guidelines. Obstet Gynecol 2000;95:377-82
42. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-9
43. Murch SH. Toll of allergy reduced by probiotics. Lancet 2001;357:1057-9
44. Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial-prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis 2003;3:201-13
45. Schrag SJ. The past and future of perinatal group B streptococcal disease prevention. Clin Infect Dis 2004;39:1136-8
46. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976;294:753-6
47. Schuchat A, Wenger JD. Epidemiology of group B streptococcal disease: risk factors, prevention strategies and vaccine development. Epidemiol Rev 1994;16:374-402
48. Lin FY, Philips III JB, Azimi PH, et al. Level of maternal antibody required to protect neonates against early onset disease caused by group B streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 2001;184:1022-8
49. Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996;98:2308-14
50. Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysccharide of group B streptococcus in infant infection. Pediatrics 1981;68:544-9
51. Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med 1988;319:1180-5
52. Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999;179:142-50
53. Baker CJ, Paoletti LC, Rench MA, et al. Use of capsular polysaccharide-tetanus conjugate vaccine for type II group B streptococcus in healthy women. J Infect Dis 2000;182:1129-38
54. Kong F, Gowan S, Martin D, James G, Gilbert GL. Molecular profiles of group B streptococcal surface protein antigen genes: relationship to molecular serotypes. J Clin Microbiol 2002;40:620-6
55. Wald N, Leck I. Conclusions. In: Wald N, Leck I, eds. Antenatal and Neonatal Screening. 2nd edn. Oxford: Oxford University Press, 2000